Table 2.
Immunotherapy clinical trials in metastatic breast cancer. • = designate if multitherapy or mono-therapy was delivered.
| Breast Cancer Stage | Immunotherapeutic | Therapy Type | Reference | ||||
|---|---|---|---|---|---|---|---|
| PD-L1 Inhibitor | PD-1 Inhibitor | CTLA-4 Inhibitor | Mono-Therapy | Multi-Therapy | |||
| Phase 1 | Early | ||||||
| Atezolizumab | • | NCT03802604 | |||||
| Locally Advanced | |||||||
| Atezolizumab | • | NCT03800836 | |||||
| Durvalumab | • | NCT03356860 | |||||
| M7824 | • | NCT02699515 | |||||
| Pembrolizumab | • | NCT03310957 | |||||
| Metastatic | |||||||
| Atezolizumab | • | NCT03853707 | |||||
| Avelumab | • | NCT04360941 | |||||
| Nivolumab | • | NCT02393794 | |||||
| Pembrolizumab | • |
NCT03362060 NCT03272334 |
|||||
| Not Specified | |||||||
| Pembrolizumab | • | NCT06246968 | |||||
| Phase 2 | Early | ||||||
| Avelumab | • | NCT04841148 | |||||
| Pembrolizumab | • | NCT05675579 | |||||
| Locally Advanced | |||||||
| Atezolizumab | • |
NCT02924883 NCT03424005 |
|||||
| Pembrolizumab | • | 3 | |||||
| Metastatic | |||||||
| Atezolizumab | • | NCTT0294883 | |||||
| Avelumab | • |
NCT04215146 NT03147287 |
|||||
| Ipilimumab | • | NCT03789110 | |||||
| Nivolumab | • | NCT03316586 | |||||
| Pembrolizumab | • | • |
NCT03139851 NCT02447003 |
||||
| Not Specified | |||||||
| Atezolizumab | • | NCT03170960 | |||||
| Ipilimumab | • | NCT03815890 | |||||
| Nivolumab | • |
NCT03815890 NCT03742968 |
|||||
| Pembrolizumab | • | NCT03025035 | |||||
| Phase 3 | Early | ||||||
| Atezolizumab | • |
NCT03726879 NCT03595592 |
|||||
| Nivolumab | • | NCT04109066 | |||||
| Pembrolizumab | • | NCT03725059 | |||||
| Locally Advanced | |||||||
| Atezolizumab | • |
NCT04148911 NCT03125902 |
|||||
| Pembrolizumab | • |
NCT05382286 NCT03036488 |
|||||
| Metastatic | |||||||
| Atezolizumab | • |
NCT04177108 NCT04740918 |
|||||